NASDAQ:WVE Wave Life Sciences (WVE) Stock Price, News & Analysis → Bible Shocker: Have You Seen Elon Musk’s Miracle? (From InvestorPlace) (Ad) Free WVE Stock Alerts $6.26 +0.36 (+6.10%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$5.82▼$6.3350-Day Range$4.66▼$6.8452-Week Range$3.15▼$7.67Volume1.10 million shsAverage Volume622,462 shsMarket Capitalization$766.60 millionP/E RatioN/ADividend YieldN/APrice Target$10.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Wave Life Sciences alerts: Email Address Wave Life Sciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside63.7% Upside$10.25 Price TargetShort InterestHealthy2.27% of Shares Sold ShortDividend StrengthN/ASustainability-0.58Upright™ Environmental ScoreNews Sentiment0.26Based on 12 Articles This WeekInsider TradingSelling Shares$96,437 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.85) to ($0.95) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.58 out of 5 starsMedical Sector88th out of 914 stocksPharmaceutical Preparations Industry30th out of 427 stocks 3.4 Analyst's Opinion Consensus RatingWave Life Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageWave Life Sciences has only been the subject of 4 research reports in the past 90 days.Read more about Wave Life Sciences' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.27% of the outstanding shares of Wave Life Sciences have been sold short.Short Interest Ratio / Days to CoverWave Life Sciences has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Wave Life Sciences has recently decreased by 11.75%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldWave Life Sciences does not currently pay a dividend.Dividend GrowthWave Life Sciences does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreWave Life Sciences has received a 77.37% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Wave Life Sciences is -0.58. Previous Next 1.8 News and Social Media Coverage News SentimentWave Life Sciences has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Wave Life Sciences this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for WVE on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Wave Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $96,437.00 in company stock.Percentage Held by Insiders31.10% of the stock of Wave Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions89.73% of the stock of Wave Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Wave Life Sciences' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Wave Life Sciences are expected to decrease in the coming year, from ($0.85) to ($0.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Wave Life Sciences is -12.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Wave Life Sciences is -12.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioWave Life Sciences has a P/B Ratio of 29.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Wave Life Sciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market Insidersget a piece of the profit from this land This isn’t the prettiest land on earth. But it might be the most valuable. And you don’t have to own, lease, or rent any land.Click here to see my #1 investment for 2024. About Wave Life Sciences Stock (NASDAQ:WVE)Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.Read More WVE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart WVE Stock News HeadlinesMay 19 at 6:24 AM | americanbankingnews.comWave Life Sciences (NASDAQ:WVE) Trading Up 5.8%May 17 at 4:50 AM | americanbankingnews.comWave Life Sciences (NASDAQ:WVE) Coverage Initiated at Wells Fargo & CompanyMay 15, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX), Wave Life Sciences (WVE) and GoodRx Holdings (GDRX)May 15, 2024 | benzinga.comWAVE Life Sciences Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)May 15, 2024 | markets.businessinsider.comBuy Rating on Wave Life Sciences: Promising Pipeline and Market PotentialMay 15, 2024 | msn.comWells Fargo Initiates Coverage of Wave Life Sciences (WVE) with Overweight RecommendationMay 15, 2024 | msn.comWells Fargo starts Wave Life Sciences at buy, cites valuationMay 12, 2024 | finance.yahoo.comWave Life Sciences Ltd. (NASDAQ:WVE) Just Reported First-Quarter Earnings And Analysts Are Lifting Their EstimatesMay 12, 2024 | americanbankingnews.comWave Life Sciences (NASDAQ:WVE) Stock Rating Lowered by StockNews.comMay 11, 2024 | markets.businessinsider.comBuy Rating Affirmed on Wave Life Sciences with Promising Obesity and AATD ProgramsMay 9, 2024 | msn.comWVE Stock Earnings: WAVE Life Sciences Misses EPS, Misses Revenue for Q1 2024May 9, 2024 | globenewswire.comWave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 9, 2024 | globenewswire.comWave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific OfficerMay 7, 2024 | globenewswire.comWave Life Sciences to Present at 2024 RBC Capital Markets Global Healthcare ConferenceMay 2, 2024 | globenewswire.comWave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024April 30, 2024 | globenewswire.comWave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD)April 30, 2024 | forbes.comSecond Chance At Life Powers Woman To Develop Award-Winning Wave Energy TechnologyApril 26, 2024 | markets.businessinsider.comBuy Rating Affirmed: Strategic Partnerships and Clinical Milestones Propel Wave Life Sciences’ Growth PotentialApril 26, 2024 | msn.comPalm Springs Surf Club Wave Pool Once Again Non-OperationalApril 23, 2024 | globenewswire.comWave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA EditingApril 20, 2024 | investing.comWave Life Sciences Ltd (WVE)April 20, 2024 | yahoo.comSurfer Rides 93.73 Foot Wave. New Record for Biggest Ever?April 16, 2024 | money.usnews.comWave Life Sciences Ltd.April 13, 2024 | morningstar.comWAVE Life Sciences LtdApril 7, 2024 | investing.comWave Life Sciences CFO sells shares worth over $96kSee More Headlines Receive WVE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Wave Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today5/18/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:WVE CUSIPN/A CIK1631574 Webwww.wavelifesciences.com Phone(656) 236-3388Fax617-949-2901Employees266Year FoundedN/APrice Target and Rating Average Stock Price Target$10.25 High Stock Price Target$17.00 Low Stock Price Target$5.00 Potential Upside/Downside+63.7%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-57,510,000.00 Net Margins-54.61% Pretax Margin-55.21% Return on EquityN/A Return on Assets-26.24% Debt Debt-to-Equity RatioN/A Current Ratio1.19 Quick Ratio1.26 Sales & Book Value Annual Sales$113.31 million Price / Sales6.77 Cash FlowN/A Price / Cash FlowN/A Book Value$0.21 per share Price / Book29.81Miscellaneous Outstanding Shares122,460,000Free Float84,375,000Market Cap$766.60 million OptionableOptionable Beta-0.99 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Paul B. Bolno M.B.A. (Age 50)M.D., President, CEO & Director Comp: $1.1MMr. Kyle B. Moran CFA (Age 53)CFO & Principal Accounting Officer Comp: $677.87kDr. Chandra Vargeese Ph.D. (Age 63)Chief Technology Officer Comp: $710.05kKate RauschHead of Investor RelationsMs. Linda Rockett J.D.Senior VP & General CounselDr. Christopher Francis Ph.D. (Age 46)Senior VP of Corporate Development & Head of Emerging Areas Comp: $493.13kMs. Daryn LewisSenior VP & Head of Human ResourcesDr. Sridhar Vaddeboina Ph.D.Senior Vice President of Chemistry, Manufacturing & ControlsMs. Anne-Marie Li-Kwai-CheungChief Development OfficerDr. Hsiu-Chiung Yang Ph.D.Senior Vice President of Translational MedicineMore ExecutivesKey CompetitorsNuvation BioNYSE:NUVBSage TherapeuticsNASDAQ:SAGECogent BiosciencesNASDAQ:COGTCureVacNASDAQ:CVACNurix TherapeuticsNASDAQ:NRIXView All CompetitorsInsiders & InstitutionsArtal Group S.A.Bought 1,044,000 shares on 5/17/2024Ownership: 3.308%Ikarian Capital LLCBought 590,088 shares on 5/17/2024Ownership: 0.482%Jacobs Levy Equity Management Inc.Bought 29,483 shares on 5/16/2024Ownership: 0.198%Price T Rowe Associates Inc. MDBought 233,891 shares on 5/15/2024Ownership: 1.520%Affinity Asset Advisors LLCBought 286,585 shares on 5/15/2024Ownership: 0.234%View All Insider TransactionsView All Institutional Transactions WVE Stock Analysis - Frequently Asked Questions Should I buy or sell Wave Life Sciences stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Wave Life Sciences in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" WVE shares. View WVE analyst ratings or view top-rated stocks. What is Wave Life Sciences' stock price target for 2024? 8 brokers have issued 1 year target prices for Wave Life Sciences' stock. Their WVE share price targets range from $5.00 to $17.00. On average, they anticipate the company's share price to reach $10.25 in the next twelve months. This suggests a possible upside of 63.7% from the stock's current price. View analysts price targets for WVE or view top-rated stocks among Wall Street analysts. How have WVE shares performed in 2024? Wave Life Sciences' stock was trading at $5.05 on January 1st, 2024. Since then, WVE shares have increased by 24.0% and is now trading at $6.26. View the best growth stocks for 2024 here. When is Wave Life Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our WVE earnings forecast. How were Wave Life Sciences' earnings last quarter? Wave Life Sciences Ltd. (NASDAQ:WVE) posted its quarterly earnings results on Thursday, May, 9th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.18) by $0.06. The business had revenue of $12.54 million for the quarter, compared to analyst estimates of $25.67 million. During the same quarter last year, the business earned ($0.27) earnings per share. What ETFs hold Wave Life Sciences' stock? ETFs with the largest weight of Wave Life Sciences (NASDAQ:WVE) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN).Invesco Nasdaq Future Gen 200 ETF (QQQS). What is Paul Bolno, M.D., MBA's approval rating as Wave Life Sciences' CEO? 17 employees have rated Wave Life Sciences Chief Executive Officer Paul Bolno, M.D., MBA on Glassdoor.com. Paul Bolno, M.D., MBA has an approval rating of 92% among the company's employees. This puts Paul Bolno, M.D., MBA in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Wave Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Wave Life Sciences investors own include Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), VBI Vaccines (VBIV), Aduro Biotech (ADRO), Cidara Therapeutics (CDTX), CRISPR Therapeutics (CRSP) and ImmunoGen (IMGN). Who are Wave Life Sciences' major shareholders? Wave Life Sciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include M28 Capital Management LP (5.72%), Bellevue Group AG (3.34%), Artal Group S.A. (3.31%), Price T Rowe Associates Inc. MD (1.52%), Vanguard Group Inc. (1.50%) and Platinum Investment Management Ltd. (0.49%). Insiders that own company stock include Chandra Vargeese, Chris Francis, Kyle Moran, Paul Bolno and Ra Capital Management, LP. View institutional ownership trends. How do I buy shares of Wave Life Sciences? Shares of WVE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:WVE) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsDems have chosen Biden replacement?Paradigm Press[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaBuy this small stock before coming AI Tidal WaveChaikin AnalyticsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Wave Life Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.